On September 21^st the Patent Office of the Republic of Poland granted a patent (number P. 414785) for an invention entitled: “Application of 3-(dodecylsulfanyl)-butanoic acid as a medicine for prevention of insulin resistance and pharmaceutical composition containing 3-(dodecylsulfanyl)-butanoic 3-(dodecylsulfanyl)-butanoic acidacid  as an active ingredient”. Patent application was submitted to the Patent Office jointly by the Nencki Institute of Experimental Biology and the University of Warmia and Mazury (UWM) in Olsztyn. The authors of this invention are prof. Krzysztof Zabłocki from the Nencki Institute and Dr. Janusz Wasilewski from the Faculty of Biology and Biotechnology, UWM.